BACKGROUND: Several biological pathways are activated concomitantly during left ventricular (LV) remodeling. However, the relative contribution of circulating biomarkers representing these distinct pathways to LV geometry is unclear. METHODS AND RESULTS: We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination. LV geometry was defined on the basis of sex-specific distributions of LV mass (LVM) and relative wall thickness (RWT): normal (LVM and RWT <80th percentile), concentric remodeling (LVM <80th percentile but RWT >or=80th percentile), eccentric hypertrophy (LVM >or=80th percentile but RWT <80th percentile), and concentric hypertrophy (LVM and RWT >or=80th percentile). We related the biomarker panel to LV geometry using polytomous logistic regression adjusting for clinical covariates and used backwards elimination to identify a parsimonious set of biomarkers associated with LV geometry. Modeled individually, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, and ARR were related to LV geometry (P<0.01). In multivariable analyses, the biomarker panel was significantly related to altered LV geometry (P<0.0001). On backwards elimination, logARR alone was significantly and positively associated with eccentric (odds ratio per SD increment, 1.20; 95% confidence interval, 1.05 to 1.37) and concentric LV hypertrophy (odds ratio per SD increment, 1.29; 95% confidence interval, 1.06 to 1.58). CONCLUSIONS: Our cross-sectional observations on a large community-based sample identified ARR as a key correlate of concentric and eccentric LV hypertrophy, consistent with a major role for the renin-angiotensin-aldosterone system in LV remodeling.
BACKGROUND: Several biological pathways are activated concomitantly during left ventricular (LV) remodeling. However, the relative contribution of circulating biomarkers representing these distinct pathways to LV geometry is unclear. METHODS AND RESULTS: We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination. LV geometry was defined on the basis of sex-specific distributions of LV mass (LVM) and relative wall thickness (RWT): normal (LVM and RWT <80th percentile), concentric remodeling (LVM <80th percentile but RWT >or=80th percentile), eccentric hypertrophy (LVM >or=80th percentile but RWT <80th percentile), and concentric hypertrophy (LVM and RWT >or=80th percentile). We related the biomarker panel to LV geometry using polytomous logistic regression adjusting for clinical covariates and used backwards elimination to identify a parsimonious set of biomarkers associated with LV geometry. Modeled individually, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, and ARR were related to LV geometry (P<0.01). In multivariable analyses, the biomarker panel was significantly related to altered LV geometry (P<0.0001). On backwards elimination, logARR alone was significantly and positively associated with eccentric (odds ratio per SD increment, 1.20; 95% confidence interval, 1.05 to 1.37) and concentric LV hypertrophy (odds ratio per SD increment, 1.29; 95% confidence interval, 1.06 to 1.58). CONCLUSIONS: Our cross-sectional observations on a large community-based sample identified ARR as a key correlate of concentric and eccentric LV hypertrophy, consistent with a major role for the renin-angiotensin-aldosterone system in LV remodeling.
Authors: Thomas J Wang; Philimon Gona; Martin G Larson; Daniel Levy; Emelia J Benjamin; Geoffrey H Tofler; Paul F Jacques; James B Meigs; Nader Rifai; Jacob Selhub; Sander J Robins; Christopher Newton-Cheh; Ramachandran S Vasan Journal: Hypertension Date: 2007-01-22 Impact factor: 10.190
Authors: J M Gardin; R McClelland; D Kitzman; J A Lima; W Bommer; H S Klopfenstein; N D Wong; V E Smith; J Gottdiener Journal: Am J Cardiol Date: 2001-05-01 Impact factor: 2.778
Authors: Erik Ingelsson; Michael J Pencina; Geoffrey H Tofler; Emelia J Benjamin; Katherine J Lanier; Paul F Jacques; Caroline S Fox; James B Meigs; Daniel Levy; Martin G Larson; Jacob Selhub; Ralph B D'Agostino; Thomas J Wang; Ramachandran S Vasan Journal: Circulation Date: 2007-08-13 Impact factor: 29.690
Authors: Steven M Kawut; R Graham Barr; W Craig Johnson; Harjit Chahal; Harikrishna Tandri; Aditya Jain; Michael R Bristow; Jorge R Kizer; Emilia Bagiella; Joao A C Lima; David A Bluemke Journal: Biomarkers Date: 2010-10-05 Impact factor: 2.658
Authors: Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett Journal: Hypertension Date: 2014-11-03 Impact factor: 10.190
Authors: Á Aceña; A M Pello; R Carda; Ó Lorenzo; M L Gonzalez-Casaus; L M Blanco-Colio; J L Martín-Ventura; J Palfy; M Orejas; R Rábago; E Gonzalez-Parra; I Mahíllo-Fernández; J Farré; J Egido; J Tuñón Journal: J Nutr Health Aging Date: 2016 Impact factor: 4.075